Mizuho Reiterates Hold Rating for Concert Pharmaceuticals (CNCE)
Mizuho reiterated their hold rating on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a research report report published on Thursday. They currently have a $23.00 price objective on the biotechnology company’s stock.
CNCE has been the topic of a number of other research reports. BidaskClub raised shares of Concert Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Saturday, December 9th. Zacks Investment Research raised shares of Concert Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, February 12th. TheStreet raised shares of Concert Pharmaceuticals from a c+ rating to a b- rating in a research note on Monday, January 8th. UBS Group set a $34.00 target price on shares of Concert Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, December 19th. Finally, ValuEngine cut shares of Concert Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Concert Pharmaceuticals presently has a consensus rating of Buy and an average price target of $25.00.
Concert Pharmaceuticals (CNCE) traded up $1.55 during midday trading on Thursday, reaching $22.59. 658,644 shares of the company were exchanged, compared to its average volume of 305,596. Concert Pharmaceuticals has a twelve month low of $9.50 and a twelve month high of $30.71.
In other Concert Pharmaceuticals news, Director Ronald W. Barrett sold 14,156 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $24.70, for a total transaction of $349,653.20. Following the sale, the director now directly owns 3,539 shares of the company’s stock, valued at $87,413.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard Aldrich sold 5,000 shares of the company’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $20.46, for a total transaction of $102,300.00. Following the sale, the director now directly owns 286,975 shares in the company, valued at $5,871,508.50. The disclosure for this sale can be found here. Insiders have sold 1,433,248 shares of company stock worth $37,226,329 over the last ninety days. Insiders own 10.10% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new stake in Concert Pharmaceuticals during the fourth quarter worth about $329,000. MetLife Investment Advisors LLC bought a new stake in Concert Pharmaceuticals during the fourth quarter worth about $232,000. Gotham Asset Management LLC bought a new stake in Concert Pharmaceuticals during the fourth quarter worth about $402,000. Metropolitan Life Insurance Co. NY bought a new stake in Concert Pharmaceuticals during the fourth quarter worth about $164,000. Finally, Jane Street Group LLC bought a new stake in Concert Pharmaceuticals during the fourth quarter worth about $451,000. 76.61% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/mizuho-reiterates-hold-rating-for-concert-pharmaceuticals-cnce/1907322.html.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.